Positive Proof of Concept for NutriLeads Key Ingredient

53a38dad-9600-4b5d-b8ca-7a91174f66b9articleimage.jpg

02 Jan 2016 --- Nutrition and health start-up NutriLeads is celebrating the beginning of 2017 following the positive findings of a proof of concept study for humans in connection with the lead ingredient Immuno Modulatory Plant Polysaccharide-1(IMPP-1).

Clinical research company analyze & realize GmbH, the partner in the clinical study, says IMPP-1  is safe, well tolerated and supports immune function in humans.

NutriLeads develops nutritional ingredients for application in health-promoting food products. Initially founded in 2012 based upon an invention originating from Unilever, NutriLeads closed a successful seed financing round with an investor syndicate comprising Thuja Capital, DSM Venturing BV, PPM Oost and Shift Invest in 2015 and is currently discussing a series A financing.

As a clinical research organization and consulting firm specialized in natural health products, analyze & realize GmbH was the selected partner to conduct the clinical study at its own study center in Berlin. In an overall project duration of one year, a&r’s R&D clinical department investigated IMPP-1 in healthy humans and proved with success the concept of the natural ingredient being supportive of immune function in humans.

NutriLeads is developing this patented ingredient for different food applications including dietary supplements, medical food and functional food to reach various target populations. 

IMPP-1 can be sustainably sourced from food crops.
 
The results of the first proof of concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system.
 
“The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products”, says Ruud Albers, PhD, CEO of NutriLeads.
 
NutriLeads, as consortium leader, and four European partners – including a&r – have been awarded a €2 million Eurostars project called NIMF. 

The consortium will develop NutriLeads’ proprietary ingredient IMPP-1 into a new ingredient for medical food products to fight impaired immune function as a result of malnutrition (particularly common in a variety of patient groups).

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Weekly Roundup: US consumers rank clean water as top health desire, Australia's Freedom Foods acquires protein product brand Crankt

17 Aug 2018 --- The weekly roundup is NutritionInsight's collection of global nutrition stories from the past week. A Nestlé Waters commissioned survey has found that clean water is the most important health factor to US consumers. Australia based Freedom Foods has acquired protein product brand Crankt to strengthen its position in the sports nutrition market. CBI and Campden BRI are teaming up for a Colombian product development workshop and the Council for Responsible Nutrition (CRN) has announced eleven new additions to its membership ranks.

Health & Nutrition News

Molecular switch may serve as new target point for obesity and diabetes therapies, says study

16 Aug 2018 --- A mechanism of the PI3KC2A kinase enzyme may have significance for the future development of therapies against cancer, obesity and diabetes, research published in Molecular Cell has found. The study highlights how if specific signaling cascades are misregulated, diseases and metabolic disorders may occur. The identified mechanism may have a crucial influence on such signaling cascades.

Health & Nutrition News

ADM strengthens gut health strategy with US$235m Probiotics International acquisition

16 Aug 2018 --- Adding to a list of microbiome strategy investments, Archer Daniels Midland Company (ADM) has completed its acquisition of Probiotics International Limited (PIL) – known under its umbrella brand Protexin – in a US$235 million deal.

Health & Nutrition News

Omega 3 platforms: BASF targets Non-Alcoholic Fatty Liver Disease as scientific support behind intervention grows

16 Aug 2018 --- BASF is targeting Non-Alcoholic Fatty Liver Disease (NAFLD) with Hepaxa, its first-to-market omega 3 product dedicated to the dietary management of the disease. Hepaxa increases the levels of fatty omega 3 acids in patients, which improves the liver's ability to process fat. Importantly, Hepaxa is manufactured using a patented purification technology which removes certain pollutants known to harm NAFLD patients. A recent meta-analysis of 18 studies, in part funded by BASF, has highlighted the importance of omega 3 intakes among people who have NAFLD.

Health & Nutrition News

Morning workout: Speed up your metabolism with breakfast, study suggests

15 Aug 2018 --- Eating breakfast before exercise may “prime” the body to burn carbohydrates during exercise and more rapidly digest, absorb and metabolize food after working out, University of Bath researchers have shown in a study published in American Journal of Physiology: Endocrinology and Metabolism.

More Articles
URL : http://www.nutritioninsight.com:80/news/positive-proof-of-concept-for-nutrileads-key-ingredient.html